SAR121

Sanofi

Product vision
  • Part of a single-exposure radical cure

MoA
  • Unknown. Inability to select resistant mutants.

Key features
  • Rapid parasite killing in vitro and clearance in vivo

  • Long predicted human half-life

  • Predicted dose to give coverage above Minimal Parasiticidal Concentration for > 8 days is 80mg

Status
  • Preclinical development

Next milestone
  • Proceed to first-in-human studies

Previously
  • MMV688533, Full reference is SAR 441121

MMV Project Director
  • Dr Cristina Donini